Wyoming AG announces Sanofi settlement on insulin costs

CHEYENNE (WNE) — Attorney General Bridget Hill announced a settlement with Sanofi-Aventis U.S. LLC (Sanofi), which guarantees that Wyoming residents not enrolled in government health care programs can buy Sanofi’s insulin products for $35 per month for the next five years.

The soaring cost of insulin over the last decade has increased scrutiny on insulin manufacturers and pharmacy benefits managers from the Attorney General’s office and other attorneys general around the nation.

Concerns arose regarding whether insulin manufacturers deceptively priced their insulin products, requiring citizens to pay inordinately high prices for insulin. This settlement is a result of those concerns.

The terms of the settlement will come into effect within 90 days of Sept. 27.

The settlement requires Sanofi to provide insulin products — including Admelog, Lantus, Toujeo, Apidra and any biosimilar of those products that Sanofi markets in the U.S. — at $35 per monthly prescription for customers choosing to pay with cash. To take advantage of the pricing, consumers will need to register for a savings card on a Sanofi affordability website. Once Sanofi’s affordability program is in place for Wyoming, the Attorney General’s office will release additional information about how Wyoming residents can purchase a month’s supply of Sanofi insulin for $35.

In addition to the $35 monthly prescription rate, Sanofi has agreed to implement an enrollment message program to assist pharmacists and patients in determining eligibility for its low-cost insulin.

The system will alert patients about this low-cost alternative at pharmacy counters throughout the state when patients are filling their prescriptions.

Sanofi has also committed to continuing its Patient Connection Program that provides free insulin to Wyoming citizens in financial need.

This story was published on October 5, 2024.